Singapore markets closed

CytomX Therapeutics Inc (6C1.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
1.27000.0000 (0.00%)
At close: 08:14PM CEST
Full screen
Previous close1.2700
Open1.2690
Bid1.2920 x 0
Ask1.3200 x 0
Day's range1.2690 - 1.3120
52-week range0.9730 - 4.4380
Volume1,300
Avg. volume3,694
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date06 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

    SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024, at 2:00 p.m. ET. A live webcast of the presentation will be available on the Events and Presenta

  • GlobeNewswire

    CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

    SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024. “Chris has made broad contributions as a member of the CytomX executive team and is a proven cross-functional leader within the organization,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX. “We are ex

  • Simply Wall St.

    Shareholders in CytomX Therapeutics (NASDAQ:CTMX) are in the red if they invested five years ago

    We're definitely into long term investing, but some companies are simply bad investments over any time frame. We really...